CIM
BIO icon

Calvert Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Calvert Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,672
Closed -$305K – 88
2016
Q4 		$305K Buy
1,672
+46
+3% +$7.84K 0.01% 664
2016
Q3 		$266K Buy
+1,626
New +$247K 0.01% 693

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Calvert Investment Management's BIO Position: Q1 2017 in Review

Calvert Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2017, closing a stake of 1,672 shares — an estimated $305K sold.

Calvert Investment Management first reported a position in BIO in Q3 2016 and held it in 2 quarters. The position peaked at $305K in Q4 2016. 274 funds tracked by Wall St. Rank hold BIO as of Q1 2017.

  • Calvert Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 1,672 Bio-Rad Laboratories Class A shares in Q1 2017, an estimated $305K.
  • Calvert Investment Management first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and held it in 2 quarters.
  • Calvert Investment Management's Bio-Rad Laboratories Class A position peaked at $305K in Q4 2016.
  • 274 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.